Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Milton

Showing results (111-120 of 182) with videos related to

Pageof 19
Sort By:
Investigational New Drugs|February 20, 2025
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Haematologica|August 19, 2021
Melphalan dose intensity for autologous stem cell transplantation in multiple myelomaSamer A Srour, Denái R Milton, Qaiser Bashir, et al.
Investigational New Drugs|September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2019
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up ResultsKamal Chamoun, Denái R Milton, Celina Ledesma, et al.
Bone Marrow Transplantation|September 28, 2018
Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndromePiyanuch Kongtim, Simrit Parmar, Denái R Milton, et al.
Journal of Cutaneous Pathology|January 11, 2024
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotinWoo Cheal Cho, Rayan Saade, Priyadharsini Nagarajan, et al.
Bone Marrow Transplantation|May 17, 2023
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplantTaha Al-Juhaishi, Yingjun Wang, Denái R Milton, et al.
Investigational New Drugs|November 3, 2021
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Leukemia & Lymphoma|July 9, 2019
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 yearsQaiser Bashir, Kamal Chamoun, Denái R Milton, et al.
Pageof 19

Showing results (111-120 of 182) with videos related to

Sort By:
Pageof 19
Investigational New Drugs|February 20, 2025
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Haematologica|August 19, 2021
Melphalan dose intensity for autologous stem cell transplantation in multiple myelomaSamer A Srour, Denái R Milton, Qaiser Bashir, et al.
Investigational New Drugs|September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2019
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up ResultsKamal Chamoun, Denái R Milton, Celina Ledesma, et al.
Bone Marrow Transplantation|September 28, 2018
Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndromePiyanuch Kongtim, Simrit Parmar, Denái R Milton, et al.
Journal of Cutaneous Pathology|January 11, 2024
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotinWoo Cheal Cho, Rayan Saade, Priyadharsini Nagarajan, et al.
Bone Marrow Transplantation|May 17, 2023
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplantTaha Al-Juhaishi, Yingjun Wang, Denái R Milton, et al.
Investigational New Drugs|November 3, 2021
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Cancer|May 18, 2017
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myelomaLauren W Veltri, Denái R Milton, Ruby Delgado, et al.
Leukemia & Lymphoma|July 9, 2019
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 yearsQaiser Bashir, Kamal Chamoun, Denái R Milton, et al.
Pageof 19